MX2020006219A - Derivados de 1-piperidinocarbonilmetil)-2-oxopiperazina para tratar cancer. - Google Patents

Derivados de 1-piperidinocarbonilmetil)-2-oxopiperazina para tratar cancer.

Info

Publication number
MX2020006219A
MX2020006219A MX2020006219A MX2020006219A MX2020006219A MX 2020006219 A MX2020006219 A MX 2020006219A MX 2020006219 A MX2020006219 A MX 2020006219A MX 2020006219 A MX2020006219 A MX 2020006219A MX 2020006219 A MX2020006219 A MX 2020006219A
Authority
MX
Mexico
Prior art keywords
piperidinocarbonylmethyl
treating cancer
oxopiperazine derivatives
oxopiperazine
derivatives
Prior art date
Application number
MX2020006219A
Other languages
English (en)
Inventor
Ulrich Kessler
Farman Ullah
Marc Labelle
Matinder Kaur
K Twibanire Jean - D''amour
Valentino Cattori
Cyril Cook
Ramkrishna Reddy Vakiti
Kevin R D Johnson
Original Assignee
Inthera Bioscience AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inthera Bioscience AG filed Critical Inthera Bioscience AG
Publication of MX2020006219A publication Critical patent/MX2020006219A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/113—Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D497/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D497/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D497/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

La presente invención se refiere a nuevos compuestos de la fórmula (I) o la fórmula (Ia). (Ver Fórmula). sus sales, hidratos, solvatos o estereoisómeros farmacéuticamente aceptables y composiciones farmacéuticas de estos compuestos que son de utilidad para uso preventivo y terapéutico en medicina humana y veterinaria.
MX2020006219A 2017-12-15 2018-12-17 Derivados de 1-piperidinocarbonilmetil)-2-oxopiperazina para tratar cancer. MX2020006219A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762599336P 2017-12-15 2017-12-15
CH1522018 2018-02-08
PCT/US2018/066027 WO2019118973A1 (en) 2017-12-15 2018-12-17 1 -(piperidinocarbonylmethyl)-2-oxopiperazine derivatives for treating cancer

Publications (1)

Publication Number Publication Date
MX2020006219A true MX2020006219A (es) 2020-12-03

Family

ID=65003562

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020006219A MX2020006219A (es) 2017-12-15 2018-12-17 Derivados de 1-piperidinocarbonilmetil)-2-oxopiperazina para tratar cancer.

Country Status (15)

Country Link
US (3) US10710975B2 (es)
EP (1) EP3724178B1 (es)
JP (1) JP7307744B2 (es)
KR (1) KR20200101397A (es)
CN (1) CN111788191B (es)
AU (1) AU2018386327B2 (es)
BR (1) BR112020011925A2 (es)
CA (1) CA3085481A1 (es)
IL (1) IL275337B2 (es)
MA (1) MA51139A (es)
MX (1) MX2020006219A (es)
RU (1) RU2020123261A (es)
SG (1) SG11202005365WA (es)
TW (1) TWI810229B (es)
WO (1) WO2019118973A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019118973A1 (en) 2017-12-15 2019-06-20 Inthera Bioscience AG 1 -(piperidinocarbonylmethyl)-2-oxopiperazine derivatives for treating cancer
WO2020048827A1 (en) 2018-09-03 2020-03-12 Bayer Aktiengesellschaft 1, 3, 9-triazaspiro[5.5] undecan-2-one compounds
WO2020048826A1 (en) 2018-09-03 2020-03-12 Bayer Aktiengesellschaft 5-substituted 1-oxa-3,9-diazaspiro[5.5]undecan-2-one compounds
WO2020048830A1 (en) 2018-09-03 2020-03-12 Bayer Aktiengesellschaft 5-aryl-3,9-diazaspiro[5.5]undecan-2-one compounds
WO2020048828A1 (en) 2018-09-03 2020-03-12 Bayer Pharma Aktiengesellschaft 5-heteroaryl-3,9-diazaspiro[5.5]undecane compounds
WO2020048829A1 (en) 2018-09-03 2020-03-12 Bayer Aktiengesellschaft 3,9-diazaspiro[5.5]undecane compounds
WO2020048831A1 (en) 2018-09-03 2020-03-12 Bayer Aktiengesellschaft 5-aryl-3,9-diazaspiro[5.5]undecan-2-one compounds
WO2021144302A1 (en) * 2020-01-13 2021-07-22 Inthera Bioscience AG Biomarkers for determining susceptibility to oxopiperazine derivatives and methods of using same
EP4168014A1 (en) * 2020-06-19 2023-04-26 Inthera Bioscience AG Oxopiperazine derivatives for the treatment of cancer
US20240122941A1 (en) * 2020-12-25 2024-04-18 National Cancer Center Therapy based on synthetic lethality in swi/snf complex-dysfunction cancer
WO2024015229A1 (en) * 2022-07-15 2024-01-18 Sutro Biopharma, Inc. Protease/enzyme cleavable linker-payloads and protein conjugates
WO2024056732A1 (en) * 2022-09-16 2024-03-21 Syngenta Crop Protection Ag Pesticidally active cyclic amine compounds

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5885995A (en) 1996-04-03 1999-03-23 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
AU2002332640B2 (en) 2001-08-24 2007-11-08 University Of South Florida Piperazinone compounds as anti-tumor and anti-cancer agents and methods of treatment
CA2463626C (en) * 2001-10-17 2011-05-24 Schering Corporation Piperidine- and piperazineacetamines as 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
ATE469886T1 (de) * 2002-11-18 2010-06-15 Schering Corp 17beta-hydroxysteroid dehydrogenase typ-3 hemmer zur behandlung von androgen abhängigen erkrankungen
JP2006516632A (ja) 2003-01-30 2006-07-06 スミスクライン・ビーチャム・コーポレイション Ｎｋ−２およびｎｋ−３受容体アンタゴニストとしてのキノリン誘導体
GB0314733D0 (en) * 2003-06-24 2003-07-30 Glaxo Group Ltd Medicaments
AU2006275568A1 (en) * 2005-08-02 2007-02-08 Neurogen Corporation Dipiperazinyl ketones and related analogues
CN101341123A (zh) * 2005-12-21 2009-01-07 因塞特公司 作为趋化因子受体调节剂的3-氨基环戊烷甲酰胺
EP2889295A1 (en) 2010-08-12 2015-07-01 New York University Oligooxopiperazines and methods of making and using them
IN2013MN02170A (es) * 2011-04-21 2015-06-12 Piramal Entpr Ltd
US20150011565A1 (en) 2012-01-25 2015-01-08 Spinifex Pharmaceuticals Pty Ltd Heterocyclic Compounds and Methods For Their Use
CN104334541A (zh) * 2012-02-16 2015-02-04 纽约大学 使用低聚氧代哌嗪非肽螺旋模拟物对低氧诱导基因表达的控制
US9695153B2 (en) 2013-01-19 2017-07-04 New York University Oligooxopiperazines for p53 reactivation
US11180481B2 (en) 2014-04-15 2021-11-23 New York University Oxopiperazine helix mimetics as inhibitors of the p53-MDM2 interaction
EP3145921A4 (en) * 2014-05-21 2017-11-08 New York University Oxopiperazine helix mimetics for control of hypoxia-inducible gene expression
WO2019118973A1 (en) 2017-12-15 2019-06-20 Inthera Bioscience AG 1 -(piperidinocarbonylmethyl)-2-oxopiperazine derivatives for treating cancer
WO2021144302A1 (en) 2020-01-13 2021-07-22 Inthera Bioscience AG Biomarkers for determining susceptibility to oxopiperazine derivatives and methods of using same
EP4168014A1 (en) 2020-06-19 2023-04-26 Inthera Bioscience AG Oxopiperazine derivatives for the treatment of cancer

Also Published As

Publication number Publication date
US10710975B2 (en) 2020-07-14
JP2021506973A (ja) 2021-02-22
SG11202005365WA (en) 2020-07-29
CA3085481A1 (en) 2019-06-20
CN111788191A (zh) 2020-10-16
IL275337A (en) 2020-07-30
RU2020123261A3 (es) 2022-02-16
US20200308139A1 (en) 2020-10-01
KR20200101397A (ko) 2020-08-27
MA51139A (fr) 2020-10-21
BR112020011925A2 (pt) 2020-11-24
IL275337B1 (en) 2024-02-01
US12012393B2 (en) 2024-06-18
US20220213057A1 (en) 2022-07-07
JP7307744B2 (ja) 2023-07-12
RU2020123261A (ru) 2022-01-17
IL275337B2 (en) 2024-06-01
US11306068B2 (en) 2022-04-19
EP3724178A1 (en) 2020-10-21
CN111788191B (zh) 2024-06-04
TW201930286A (zh) 2019-08-01
AU2018386327A1 (en) 2020-06-25
EP3724178B1 (en) 2024-05-01
TWI810229B (zh) 2023-08-01
AU2018386327B2 (en) 2023-04-13
US20190185449A1 (en) 2019-06-20
WO2019118973A1 (en) 2019-06-20

Similar Documents

Publication Publication Date Title
MX2020006219A (es) Derivados de 1-piperidinocarbonilmetil)-2-oxopiperazina para tratar cancer.
EA202091491A1 (ru) Новые бензиламинозамещенные пиридопиримидиноны и производные в качестве ингибиторов sos1
PH12020551717A1 (en) Dual atm and dna-pk inhibitors for use in anti-tumor therapy
PH12015502159A1 (en) Chemical entities
PH12017500367B1 (en) Compounds that inhibit mcl-1 protein
EA201891494A1 (ru) Гетероциклические соединения в качестве иммуномодуляторов
PH12015502414A1 (en) Enhancer of zeste homolog 2 inhibitors
TN2018000119A1 (en) Dihydroimidazopyrazinone derivatives useful in the treatment of cancer
MX2018009870A (es) Inhibidores de taf1 para la terapia del cancer.
MX2020010942A (es) Inhibidores dobles de atm y adn-pk para uso en terapias antitumorales.
MX2019012847A (es) Compuestos de c5-anilinoquinazolina y su uso en el tratamiento del cancer.
PH12018502314A1 (en) Enhancer of zeste homolog 2 inhibitors
PH12019500568A1 (en) Dopamine-b-hydroxylase inhibitors
MX362896B (es) Cis-morfolinona y otros compuestos como inhibidores de mdm2 para el tratamiento del cáncer.
MX2022000390A (es) Derivados macrociclicos espirociclicos como inhibidores de mcl-1.
ZA202301066B (en) Phthalazine derivatives as inhibitors of parp1, parp2 and/or tubulin useful for the treatment of cancer
GEP20247627B (en) Macrocyclic compounds as sting agonists and methods and uses thereof
PH12020500542A1 (en) Dopamine-b-hydroxylase inhibitors
MX2019004822A (es) Derivado del pirazol 3,4-bipiridilo y metodo de preparacion del mismo y aplicacion medica del mismo.
ZA202201499B (en) Dual atm and dna-pk inhibitors for use in anti-tumor therapy
PH12016502480A1 (en) Compounds, pharmaceutical composition and their use in treating neurodegenerative diseases
MX2023007291A (es) Derivados de 4-(pirazol-5-il)-indol macrociclicos ramificados como inhibidores de mcl-1.
IN2014MN01546A (es)
EA201990763A1 (ru) Ингибиторы дофамин-в-гидроксилазы, проникающие через гематоэнцефалический барьер